|By Business Wire||
|July 30, 2014 10:39 AM EDT||
Envisia Therapeutics today announced that it has made two appointments to the company’s board of directors. Effective immediately, Adrienne Graves, Ph.D. and Gary Phillips, M.D. will join the board as non-executive members.
“We are extremely honored to have these two respected industry leaders join the Board of Directors of Envisia early in the lifecycle of our company, which we believe is paving the way for a potentially transformative line of innovative ocular therapeutics,” said Neal Fowler, Chief Executive Officer of Envisia Therapeutics. “Both appointments bring invaluable perspective and insights that are greatly complementary to that of our existing board, forming a team that will collectively help us position Envisia as a leader in developing cutting-edge solutions for the ophthalmology community.”
A global thought leader in ophthalmology, Dr. Adrienne Graves currently serves as an independent director on a number of corporate boards, including Akorn, Inc.; TearLab Corporation; Aerpio Therapeutics; and Encore Vision. She is also a director on a number of ophthalmology-related foundation boards, including the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation (GRF), American Academy of Ophthalmology (AAO) Foundation (Emeritus), Himalayan Cataract Project, and KeepYourSight Foundation. Dr. Graves also cofounded Glaucoma 360 (Glaucoma Research Foundation) and Ophthalmic Women Leaders (OWL). Additionally, she serves on the Corporation Committee for the Brown University Medical School and the Advisory Board for Amach Capital Partners.
“Much progress has been made in the field of ophthalmology; however, the rate of preventable vision loss and blindness continues to rise and underscores the near-term need for truly innovative ocular therapies,” said Adrienne Graves, Ph.D. “Envisia’s application of the PRINT® technology to address unmet needs in ophthalmology could have a profound impact on our ability to reduce the rate of preventable vision loss, and I look forward to working with the company on its efforts to achieve this worthy goal.”
Dr. Graves was formerly President and Chief Executive Officer of Santen USA, a division of Santen Co. Ltd., Japan’s largest ophthalmic pharmaceutical company. She started her successful career with Santen USA in 1995 as Vice President of Clinical Affairs with responsibility for initiating the company’s U.S. clinical program, which included the approval of three New Drug Applications. Prior to joining Santen, she spent nine years with Alcon Laboratories, Inc., beginning as a Senior Scientist and then advancing into various roles, including Director of International Ophthalmology. Dr. Graves received her AB in Psychology with honors from Brown University and her Ph.D. in Psychobiology from the University of Michigan, and she completed a postdoctoral fellowship in visual neuroscience at the University of Paris.
Dr. Gary Phillips has more than 20 years’ experience in strategy, business development and licensing, commercial operations, business analytics, and clinical medicine in the pharmaceutical and healthcare industries. He is currently the Senior Vice President and Chief Strategy Officer at Mallinckrodt Pharmaceuticals.
“The ophthalmology market is attractive and highly concentrated among a few competitors; therefore, new entrants must be clearly differentiated through improved technologies that deliver marked improvement in patient outcomes while reducing the cost burden on patients and the healthcare system,” said Gary Phillips, M.D. “Through its unique combination of talent, technology, and vision, Envisia is well positioned to compete in this market, and I look forward to working with the company’s board and management team toward the goal of maximizing its potential in the years to come.”
Before joining Mallinckrodt, Dr. Phillips served as Head of Global Health and Healthcare Industries at the World Economic Forum in Geneva, Switzerland. Previously, he was President of Reckitt Benckiser Pharmaceuticals, Inc., and held the dual roles of President, U.S. Surgical and Pharmaceuticals and Global Head of Pharmaceuticals at Bausch & Lomb Incorporated. He has also held executive roles at Merck Serono, Novartis, and Wyeth (now Pfizer) and served as a healthcare strategy management consultant at Towers Perrin (now Towers Watson) and as a medical officer with the United States Navy. Dr. Phillips attended the University of Pennsylvania, where he earned a medical degree from the School of Medicine, an MBA from the Wharton School, and a Bachelor’s degree summa cum laude in biochemistry from the College of Arts and Sciences. He completed his postgraduate medical education at Naval Medical Center San Diego.
ABOUT ENVISIA THERAPEUTICS™
Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately-held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, implantable extended-release formulation of travoprost (a marketed prostaglandin analogue) that has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina. For more information, please visit www.envisiatherapeutics.com.
Oct. 21, 2016 07:00 AM EDT Reads: 4,360
Oct. 21, 2016 06:45 AM EDT Reads: 1,774
Oct. 21, 2016 06:15 AM EDT Reads: 453
Oct. 21, 2016 06:15 AM EDT Reads: 4,611
Oct. 21, 2016 05:45 AM EDT Reads: 5,033
Oct. 21, 2016 05:00 AM EDT Reads: 3,907
Oct. 21, 2016 04:30 AM EDT Reads: 3,066
Oct. 21, 2016 04:30 AM EDT Reads: 16,196
Oct. 21, 2016 04:15 AM EDT Reads: 1,707
Oct. 21, 2016 04:00 AM EDT Reads: 10,926
@DevOpsSummit has been named the ‘Top DevOps Influencer' by iTrend. iTrend processes millions of conversations, tweets, interactions, news articles, press releases, blog posts - and extract meaning form them and analyzes mobile and desktop software platforms used to communicate, various metadata (such as geo location), and automation tools. In overall placement, @DevOpsSummit ranked as the number one ‘DevOps Influencer' followed by @CloudExpo at third, and @MicroservicesE at 24th.
Oct. 21, 2016 03:30 AM EDT Reads: 3,744
A critical component of any IoT project is what to do with all the data being generated. This data needs to be captured, processed, structured, and stored in a way to facilitate different kinds of queries. Traditional data warehouse and analytical systems are mature technologies that can be used to handle certain kinds of queries, but they are not always well suited to many problems, particularly when there is a need for real-time insights.
Oct. 21, 2016 03:15 AM EDT Reads: 3,836
One of biggest questions about Big Data is “How do we harness all that information for business use quickly and effectively?” Geographic Information Systems (GIS) or spatial technology is about more than making maps, but adding critical context and meaning to data of all types, coming from all different channels – even sensors. In his session at @ThingsExpo, William (Bill) Meehan, director of utility solutions for Esri, will take a closer look at the current state of spatial technology and ar...
Oct. 21, 2016 03:15 AM EDT Reads: 1,643
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his session at @DevOpsSummit 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will show how customers are able to achieve a level of transparency that enables everyon...
Oct. 21, 2016 02:30 AM EDT Reads: 1,205
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at @ThingsExpo, James Kirkland, Red Hat's Chief Arch...
Oct. 21, 2016 02:00 AM EDT Reads: 5,903